Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus

摘要: Abstract Background Lupus nephritis (LN) is the most common organ manifestation in systemic lupus erythematosus (SLE) and associated with a poor prognosis. Still, noninvasive but reliable method to diagnose LN has not been established. Thus, we evaluated whether blood sphingolipids could serve as valid biomarkers for renal injury. Methods In this cross-sectional study, 82 participants were divided into three groups: 36 healthy controls 17 SLE patients without injury (both: estimated glomerular filtration rate (eGFR) ≥ 80 ml/min/1.73 m2 albumin/creatinine ≤ 30 mg/g) 29  patients. identified by biopsies impaired function (eGFR 30 mg/g). Venous was collected from all sphingolipid levels plasma serum measured LC-MS/MS. Results Most interesting, concentrations of some specific ceramides, C16ceramide (Cer), C18Cer, C20Cer C24:1Cer, elevated both, samples suffering biopsy-proven function, compared well C24:1dhCer Sphingosine higher controls, Sphinganine significantly SLE. S1P SA1P controls. Subsequent ROC analyses data altered ceramide species (C16Cer, C20Cer, C24:1Cer) between display high diagnostic differentiation significant AUCs especially C24:1Cer levels. Further, affected glucocorticoid treatment did correlate other markers, such creatinine, eGFR ratio. Conclusion Our reveal that chain-length ceramides blood, likely serum, act potent impairment